NCT06004115View on ClinicalTrials.gov

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

PHASE4RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Depression, AnxietyFearDepressionAnxiety and FearAnxiety DisordersAnxious Depression
Interventions
DRUG

Lorazepam

1mg of Lorazepam will be prepared by pharmacy (Barnes, Tulsa) in capsule form

OTHER

Placebo

placebo will be prepared by pharmacy (Barnes, Tulsa) in capsule form

Trial Locations (1)

74136

RECRUITING

Laureate Institute for Brain Research, Tulsa

Sponsors
All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

collaborator

California Institute of Technology

OTHER

lead

Laureate Institute for Brain Research, Inc.

OTHER